Literature DB >> 16091251

Coronary heart disease in HIV-infected patients.

Marshall J Glesby1.   

Abstract

Increased risk of coronary heart disease has emerged as a long-term concern among HIV-infected patients receiving antiretroviral therapy. HIV-infected patients may have modifiable risk factors for heart disease that are associated with HIV itself, antiretroviral therapy, or factors unrelated to HIV. Dyslipidemia, insulin resistance, and diabetes mellitus are often multifactorial in origin. Patients with lipodystrophy frequently have a constellation of metabolic changes that may predispose them to accelerated atherosclerosis. There is also concern about contributions of chronic inflammation and prothrombotic tendencies in the pathogenesis of coronary heart disease in the HIV-infected population. Several epidemiological studies support an increased relative risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy. Although absolute risk appears low in the short term, patients may accrue significant risk over time. Clinicians are advised to assess coronary heart disease risk in HIV-infected patients and to intervene to reduce the impact of modifiable risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091251     DOI: 10.1007/s11904-005-0021-7

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  37 in total

1.  The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

Authors:  H Murata; P W Hruz; M Mueckler
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

2.  Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Authors:  Kristina Koppel; Göran Bratt; Sam Schulman; Håkan Bylund; Eric Sandström
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

3.  Acute myocardial infarction in human immunodeficiency virus-infected patients.

Authors:  Shlomo Matetzky; Michelle Domingo; Saibal Kar; Marko Noc; Prediman K Shah; Sanjay Kaul; Eric Daar; Bojan Cercek
Journal:  Arch Intern Med       Date:  2003-02-24

4.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Authors:  Mustafa A Noor; Tara Seneviratne; Francesca T Aweeka; Joan C Lo; Jean-Marc Schwarz; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

5.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

6.  Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.

Authors:  Donald P Kotler; Norma Muurahainen; Carl Grunfeld; Christine Wanke; Melanie Thompson; Michael Saag; Daena Bock; Gregg Simons; Joseph M Gertner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

7.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

8.  Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.

Authors:  Adeel A Butt; Shawn L Fultz; C Kent Kwoh; David Kelley; Melissa Skanderson; Amy C Justice
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection.

Authors:  Priscilla Y Hsue; Kamini Giri; Sara Erickson; John S MacGregor; Naji Younes; Amandeep Shergill; David D Waters
Journal:  Circulation       Date:  2004-01-12       Impact factor: 29.690

10.  Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome.

Authors:  Carmine Gazzaruso; Raffaele Bruno; Adriana Garzaniti; Stefano Giordanetti; Pietro Fratino; Paolo Sacchi; Gaetano Filice
Journal:  J Hypertens       Date:  2003-07       Impact factor: 4.844

View more
  6 in total

1.  Senescent Phenotype Induced by p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV-Positive Individuals.

Authors:  Meera V Singh; Sivareddy Kotla; Nhat-Tu Le; Kyung Ae Ko; Kyung-Sun Heo; Yin Wang; Yuka Fujii; Hang Thi Vu; Elena McBeath; Tamlyn N Thomas; Young Jin Gi; Yunting Tao; Jan L Medina; Jack Taunton; Nancy Carson; Vikram Dogra; Marvin M Doyley; Alicia Tyrell; Wang Lu; Xing Qiu; Nicole E Stirpe; Kathleen J Gates; Christine Hurley; Keigi Fujiwara; Sanjay B Maggirwar; Giovanni Schifitto; Jun-Ichi Abe
Journal:  Circulation       Date:  2019-02-26       Impact factor: 29.690

2.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

3.  The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.

Authors:  Honor Rose; Hann Low; Elizabeth Dewar; Michael Bukrinsky; Jennifer Hoy; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2013-04-17       Impact factor: 5.162

4.  HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells.

Authors:  Patrick Duffy; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Surg Res       Date:  2009-03-04       Impact factor: 2.192

5.  HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis.

Authors:  Huanhuan L Cui; Michael Ditiatkovski; Rajitha Kesani; Yuri V Bobryshev; Yingying Liu; Matthias Geyer; Nigora Mukhamedova; Michael Bukrinsky; Dmitri Sviridov
Journal:  FASEB J       Date:  2014-03-18       Impact factor: 5.191

6.  Lipid metabolism in patients infected with Nef-deficient HIV-1 strain.

Authors:  Hann Low; Lesley Cheng; Maria-Silvana Di Yacovo; Melissa J Churchill; Peter Meikle; Michael Bukrinsky; Andrew F Hill; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2015-10-30       Impact factor: 5.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.